Evelyn Fleming, MD
Gynecologic Oncology · Lebanon, NHNPI 1780616219
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Merck accounts for 71.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,540 and has fallen 75.1% since, to $384 in 2025.
Across 22 payments — averaging $95.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- AstraZeneca$259
- AbbVie$125
- Incyte Corporation$91
- Tesaro, Inc.$61
- Intuitive Surgical$48
- plus $14 from 1 others
Across 161 payments — averaging $13,561 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tesaro, Inc.$880K
- GSK$595K
- Merck$449K
- Genentech, Inc.$193K
- Eli Lilly$37K
- AstraZeneca$31K
What the payments were for
- Travel & lodging$1,19957%
- Food & beverage$73335%
- Education$1718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 12 | $1,505 |
| AstraZeneca | 5 | $259 |
| AbbVie | 1 | $125 |
| Incyte Corporation | 1 | $91 |
| Tesaro, Inc. | 1 | $61 |
| Intuitive Surgical | 1 | $48 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Lebanon
- Ilana CassLebanon$6K
- Ivy Wilkinson RyanLebanon$66
- Loyd WestLebanon$46
- Michael PearlLebanon$37
- Ariel KredentserLebanon$36
- Leslie DemarsManchester$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.